Distinct HbA1c trajectories in a type 2 diabetes cohort

Acta Diabetologica

Volumn 52, Issue 2, 2014, Pages 267-275

  Walraven, Iris ^a   Mast, M Ruth ^a   Hoekstra, Trynke ^a,b   Jansen, A P Danielle ^a   van der Heijden, Amber A W A ^a   Rauh, Simone P ^a   Rutters, Femke ^a   van ’t Riet, Esther ^a   Elders, Petra J M ^a   Moll, Annette C ^a   Polak, Bettine C P ^a   Dekker, Jacqueline M ^a   Nijpels, Giel ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Epidemiology; HbA1c; Latent class growth modeling; Longitudinal; Personalized care; Type 2 diabetes

Indexed keywords

GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

AGED; BLOOD; COHORT ANALYSIS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MALE; METABOLISM; MIDDLE AGED; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS;

AGED; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; NETHERLANDS;

EID: 84939882455     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0633-8     Document Type: Article

References (31)

1. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853
2. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703–713
3. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S (2011) Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 154:554–559
4. Kassai B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C (2011) Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343:d4169
5. Dailey G (2011) Overall mortality in diabetes mellitus: where do we stand today? Diabetes Technol Ther 13(Suppl. 1):S65–S74
6. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364–1379
7. Raz I, Riddle MC, Rosenstock J et al (2013) Personalized management of hyperglycemia in type 2 diabetes: reflections from a diabetes care editors expert forum. Diabetes Care 36:1779–1788
8. Twisk J, Hoekstra T (2012) Classifying developmental trajectories over time should be done with great caution: a comparison between methods. J Clin Epidemiol 65:1078–1087
9. Zavrelova H, Hoekstra T, Alssema M et al (2011) Progression and regression: distinct developmental patterns of diabetic retinopathy in patients with type 2 diabetes treated in the diabetes care system West-Friesland, the Netherlands. Diabetes Care 34:867–872
10. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167
11. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK (1995) Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia 38:437–444
12. Rutten GEHM, De Grauw WJC, Nijpels G et al (2006) NHG-standaard diabetes mellitus type 2. Huisarts Wet 49:137–152
13. Pani L, Nathan DM, Grant RW (2008) Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1c <7%. Diabetes Care 31:386–390
14. Blumenthal K, Larkin M, Winning G, Nathan D, Grant R (2010) Changes in glycemic control from 1996 to 2006 among adults with type 2 diabetes: a longitudinal cohort study. BMC Health Serv Res 10:158
15. Shorr RI, Franse LV, Resnick HE, Di Bari M, Johnson KC, Pahor M (2000) Glycemic control of older adults with type 2 diabetes: findings from the Third National Health and Nutrition Examination Survey, 1988–1994. J Am Geriatr Soc 48:264–267
16. Benoit S, Fleming R, Philis-Tsimikas A, Ji M (2005) Predictors of glycemic control among patients with type 2 diabetes: a longitudinal study. BMC Public Health 5:36
17. Blaum CS, Velez L, Hiss RG, Halter JB (1997) Characteristics related to poor glycemic control in NIDDM patients in community practice. Diabetes Care 20:7–11
18. Ali MK, McKeever Bullard K, Saaddine JB, Cowie CC, Imperatore G, Gregg EW (2013) Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med 368:1613–1624
19. Ekström N, Miftaraj M, Svensson A-M et al (2012) Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register. Diabetes Obes Metab 14:717–726
20. Liebl A, Mata M, Eschwege E (2002) Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 45:S23–S28
21. Yurgin N, Secnik K, Lage MJ (2007) Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. Clin Ther 29:316–325
22. van der Heijden A, de Bruijne M, Feenstra T et al (2014) Resource use and costs of type 2 diabetes patients receiving managed or protocolized primary care: a controlled clinical trial. BMC Health Serv Res 14:280
23. Saaddine JB, Cadwell B, Gregg EW et al (2006) Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002. Ann Intern Med 144:465–474
24. Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139
25. UK Prospective Diabetes Study (UKPDS) Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572
26. Stratton IM, Kohner EM, Aldington SJ et al (2001) UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 44:156–163
27. Avery CL, Kucharska-Newton A, Monda KL et al (2012) Impact of long-term measures of glucose and blood pressure on the retinal microvasculature. Atherosclerosis 225:412–417
28. Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376:124–136
29. Levin SR, Coburn JW, Abraira C et al (2000) Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on glycemic control and complications in type 2 diabetes feasibility trial investigators. Diabetes Care 23:1478–1485
30. Daniele G, Guardado Mendoza R, Winnier D et al (2014) The inflammatory status score including IL-6, TNFa, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 51:123–131
31. Fiorentino TV, Prioletta A, Zuo P, Folli F (2013) Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des 19:5695–5703